Dose Escalation Study of Cabozantinib for Advanced HCC Patients With Preserved Liver Function

NCT04522908 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

40

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma (HCC)
Second Line Treatment

Interventions

DRUG: Cabozantinib Oral Tablet

Sponsor

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Collaborators

[object Object]